Napo, AsiaPharm Group Ltd. deal

Napo granted AsiaPharm exclusive Chinese development and commercialization rights to crofelemer to treat AIDS-related diarrhea, acute infectious diarrhea and pediatric diarrhea. AsiaPharm will contribute process development, manufacturing and pediatric formulation capabilities. Napo received an equity investment and is eligible for royalties. ...